Does medication type make a difference?…
Read More »Type 2 Diabetes and Mortality Risk
Approximately two-fold increase….
Read More »Liraglutide and Pancreatitis/Pancreatic Cancer Risk
Post market study results….
Read More »DPP-4 Inhibitors in the Elderly
Tolerability in type 2 diabetes patients aged 65 years and older….
Read More »ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #17: Insulin, Part 2 of 3
Anne Peters, MD, and Lori Laffel, MD, MPH, Editors Jane Lee Chiang, MD, Managing Editor PEDIATRICS – Jane Lee Chiang, MD, and Georgeanna J. Klingensmith, MD ADULTS – Irl B. Hirsch, MD 1. Basal insulin accounts for ~50% of total daily dose: i. LAA (insulin glargine, detemir, degludec) or NPH if LAA …
Read More »What Do We Know about the Dawn Phenomenon?
Can basal insulin can make a difference?…
Read More »Risk Factors for Hypoglycemia and Strategies for Avoidance
Minimizing hypoglycemia in type 2 diabetes patients…. Hypoglycemia is a common problem among patients taking combinations of insulin and sulfonylureas and may be a limiting factor in diabetes therapy management. Hypoglycemia is defined by the American Diabetes Association (ADA) as a plasma glucose of 79mg/dL. (3.9mmol/L) or less; however most people …
Read More »Is Linagliptin Safe for the Elderly?
New research assesses safety and efficacy of linagliptin as add on treatment in elderly diabetes patients….
Read More »Exenatide: Once Weekly Dosing or Twice Daily?
Does Bydureon once weekly show benefit in type 2 diabetic patients?…
Read More »New Direction in Drug Treatment Selection for Type 2 Diabetes
Scientific understanding of the disease shifts treatment to drugs with newer mechanisms….
Read More »